REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
| Autor: | Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev, Aleksei Sergeevich Kolbin, Andrey Vladislavovich Pavlysh |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2015 |
| Předmět: |
Pharmacology
medicine.medical_specialty Cost–utility analysis business.industry Health Policy Public Health Environmental and Occupational Health cost-utility analysis rare diseases Legislation RM1-950 Orphan drug Pharmacoeconomics Economics as a science pharmacoeconomics orphan drugs Medicine Therapeutics. Pharmacology business Intensive care medicine HB71-74 Risk management Rare disease |
| Zdroj: | Фармакоэкономика, Vol 8, Iss 2, Pp 3-10 (2015) |
| ISSN: | 2070-4933 2070-4909 |
| Popis: | Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal definition of a rare disease and no universal approach to orphan drugs legislation. As a result, decision-making in this field requires results of pharmacoeconomic analysis, which structure and interpretation need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis, risk management, and international rare diseases patient registries could be used to solve these problems. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|